JP2010535012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535012A5 JP2010535012A5 JP2009551102A JP2009551102A JP2010535012A5 JP 2010535012 A5 JP2010535012 A5 JP 2010535012A5 JP 2009551102 A JP2009551102 A JP 2009551102A JP 2009551102 A JP2009551102 A JP 2009551102A JP 2010535012 A5 JP2010535012 A5 JP 2010535012A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- egfr
- composition
- separate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 2
- 102000045108 human EGFR Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 238000005580 one pot reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200700317 | 2007-03-01 | ||
| DKPA200700317 | 2007-03-01 | ||
| US90477307P | 2007-03-05 | 2007-03-05 | |
| US60/904,773 | 2007-03-05 | ||
| DKPA200701016 | 2007-07-10 | ||
| DKPA200701016 | 2007-07-10 | ||
| US92972707P | 2007-07-11 | 2007-07-11 | |
| US60/929,727 | 2007-07-11 | ||
| PCT/DK2008/050047 WO2008104183A2 (en) | 2007-03-01 | 2008-02-27 | Recombinant anti-epidermal growth factor receptor antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535012A JP2010535012A (ja) | 2010-11-18 |
| JP2010535012A5 true JP2010535012A5 (OSRAM) | 2011-04-14 |
| JP5726417B2 JP5726417B2 (ja) | 2015-06-03 |
Family
ID=39495833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551102A Active JP5726417B2 (ja) | 2007-03-01 | 2008-02-27 | 組み換え抗上皮成長因子受容体抗体組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7887805B2 (OSRAM) |
| EP (2) | EP2725036B1 (OSRAM) |
| JP (1) | JP5726417B2 (OSRAM) |
| KR (2) | KR101805140B1 (OSRAM) |
| CN (2) | CN104151430A (OSRAM) |
| AU (1) | AU2008221118B2 (OSRAM) |
| BR (1) | BRPI0808551B1 (OSRAM) |
| CA (1) | CA2676049C (OSRAM) |
| DK (1) | DK2132229T3 (OSRAM) |
| ES (1) | ES2582386T3 (OSRAM) |
| HK (1) | HK1197252A1 (OSRAM) |
| IL (2) | IL199725A (OSRAM) |
| MX (2) | MX338151B (OSRAM) |
| NZ (2) | NZ597466A (OSRAM) |
| PL (1) | PL2132229T3 (OSRAM) |
| RU (1) | RU2013119724A (OSRAM) |
| TW (1) | TWI426083B (OSRAM) |
| WO (1) | WO2008104183A2 (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PL2132229T3 (pl) * | 2007-03-01 | 2016-12-30 | Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka | |
| MX2009008908A (es) * | 2007-03-01 | 2009-08-28 | Symphogen As | Metodo para clonacion de anticuerpos analogos. |
| JP2008289483A (ja) * | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
| US20110256142A1 (en) | 2007-09-06 | 2011-10-20 | Genmab A/S | Novel methods and antibodies for treating cancer |
| WO2009086411A2 (en) * | 2007-12-27 | 2009-07-09 | Abbott Laboratories | Negative mimic antibody for use as a blocking reagent in bnp immunoassays |
| EP2331577B1 (en) | 2008-08-29 | 2017-06-07 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| MX2011001930A (es) * | 2008-08-29 | 2011-04-21 | Symphogen As | Metodo para clonar anticuerpos derivados de aves. |
| AU2009301505A1 (en) * | 2008-10-06 | 2010-04-15 | Symphogen A/S | Method for identifying and selecting drug candidates for combinatorial drug products |
| FR2942928B1 (fr) | 2009-03-03 | 2011-04-01 | Alcatel Lucent | Procede et systeme de gestion multicriteres de notifications de presence |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| US8821879B2 (en) | 2009-09-04 | 2014-09-02 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
| JP2013507603A (ja) * | 2009-10-09 | 2013-03-04 | シムフォゲン・アクティーゼルスカブ | 署名ペプチドおよび質量分析による混合物中の個々の組換えタンパク質の多重定量化 |
| WO2011106707A2 (en) * | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
| US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| US9096660B2 (en) | 2010-04-26 | 2015-08-04 | Abraxis Bioscience, Llc | SPARC binding antibodies and uses thereof |
| WO2011140151A1 (en) * | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| CN105153307A (zh) * | 2010-05-04 | 2015-12-16 | 梅里麦克制药股份有限公司 | 抗表皮生长因子受体(egfr)的抗体及其用途 |
| WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
| AU2011320314B2 (en) * | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
| EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| ES2692379T3 (es) | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anticuerpos anti-HER3 y composiciones |
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| AU2012211014A1 (en) | 2011-01-24 | 2013-05-02 | National Research Council Of Canada | Antibodies selective for cells presenting EGFR at high density |
| WO2012122484A1 (en) | 2011-03-09 | 2012-09-13 | Roberto Polakiewicz | Methods and reagents for creating monoclonal antibodies |
| JP2014508782A (ja) | 2011-03-11 | 2014-04-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 |
| CN103429262A (zh) | 2011-03-15 | 2013-12-04 | 梅里麦克制药股份有限公司 | 克服对erbb途径抑制剂的抗性 |
| US20120258502A1 (en) * | 2011-04-08 | 2012-10-11 | Vinod Pandiripally | Method of producing recombinant plasmid dna using substantially solid growth medium |
| US8691231B2 (en) * | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| SG11201402343SA (en) | 2011-11-21 | 2014-06-27 | Immunogen Inc | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| JP2015509091A (ja) * | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
| WO2013164689A2 (en) | 2012-05-02 | 2013-11-07 | Lantto, Johan | Humanized pan-her antibody compositions |
| EP2894472A4 (en) * | 2012-09-05 | 2016-03-30 | Jsr Corp | METHOD OF SCREENING MATERIAL FOR EPITHELIAL CONSERVATION OF CELLS |
| US20150293105A1 (en) * | 2012-10-26 | 2015-10-15 | The University Of Queensland | Methods for classifying tumors and uses therefor |
| CN102993305B (zh) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
| US9856319B2 (en) * | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
| CN104059148B (zh) * | 2013-03-18 | 2016-09-07 | 回而生医药科技（北京）有限公司 | 人源化抗人表皮生长因子受体抗体及其应用 |
| US20150071923A1 (en) * | 2013-09-12 | 2015-03-12 | Ge Wei | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| US20160340439A1 (en) * | 2014-01-22 | 2016-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy |
| GB201402591D0 (en) | 2014-02-14 | 2014-04-02 | Memo Therapeutics Ag | Method for recovering two or more genes, or gene products, encoding an immunoreceptor |
| ES2884930T3 (es) * | 2014-03-26 | 2021-12-13 | Siemens Healthcare Diagnostics Inc | Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y métodos de producción y uso de los mismos |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| US20170333570A1 (en) * | 2014-10-31 | 2017-11-23 | Formation Biologics Inc. | Egfr antibody-based combination therapy |
| ES2926384T3 (es) | 2015-02-06 | 2022-10-25 | Nat Univ Singapore | Métodos para mejorar la eficacia de células inmunitarias terapéuticas |
| MA41948A (fr) | 2015-04-24 | 2018-02-28 | Merrimack Pharmaceuticals Inc | Procédés de traitement de patients présentant des mutations dans le domaine extracellulaire du récepteur de facteur de croissance épidermique (egfr) avec une combinaison de trois anticorps anti-egfr monoclonaux entièrement humains |
| AU2017235450A1 (en) | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| CA3025162A1 (en) | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| SG10201912387PA (en) | 2016-11-22 | 2020-02-27 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| MY201744A (en) * | 2016-12-23 | 2024-03-15 | Visterra Inc | Binding polypeptides and methods of making the same |
| EP3585814B1 (en) * | 2017-02-22 | 2025-12-10 | University of Saskatchewan | Egfr-binding agents and uses thereof |
| WO2018166119A1 (zh) * | 2017-03-14 | 2018-09-20 | 北京伟峰益民科技有限公司 | 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用 |
| KR20200035304A (ko) | 2017-08-10 | 2020-04-02 | 싱가포르국립대학교 | T 세포 수용체-결핍 키메라 항원 수용체 t-세포 및 이의 사용 방법 |
| CN111278992A (zh) | 2017-08-30 | 2020-06-12 | 西福根有限公司 | 用抗egfr抗体治疗癌症的组合物和方法 |
| WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
| CA3089478A1 (en) * | 2018-01-25 | 2019-08-01 | Pdi Therapeutics, Inc. | Mica/b antibodies and methods of use |
| JP7584299B2 (ja) | 2018-05-23 | 2024-11-15 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現 |
| US11274035B2 (en) | 2019-04-24 | 2022-03-15 | X-Celeprint Limited | Overhanging device structures and related methods of manufacture |
| US12162747B2 (en) | 2018-12-03 | 2024-12-10 | X-Celeprint Limited | Enclosed cavity structures |
| US10456776B1 (en) | 2019-02-21 | 2019-10-29 | King Saud University | Method of fabricating a photocatalyst for water splitting |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN111018990A (zh) * | 2020-02-10 | 2020-04-17 | 张喜田 | 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用 |
| AU2022361653A1 (en) | 2021-10-04 | 2024-05-02 | Les Laboratoires Servier | Cancer therapy targeting nkg2a |
| AR127893A1 (es) | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5459061A (en) | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| DK0531472T3 (da) * | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
| WO1994000136A1 (en) | 1992-06-30 | 1994-01-06 | Oncologix, Inc. | A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2404088A1 (en) | 2000-03-23 | 2001-09-27 | Greenville Hospital System | Bi-functional cancer treatment agents |
| BR0110927A (pt) * | 2000-05-19 | 2003-03-11 | Scancell Ltd | Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| JP2004519233A (ja) | 2001-02-19 | 2004-07-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 免疫原性の低減された修飾された抗ｅｇｆｒ抗体 |
| PT1392359E (pt) | 2001-05-11 | 2010-01-27 | Ludwig Inst For Cancer Res Ltd | Proteínas de ligação específica e suas utilizações |
| CZ200438A3 (cs) * | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
| EP1482043A4 (en) * | 2002-03-01 | 2005-08-10 | Japan Enviro Chemicals Ltd | FOR BINDING TO ENVIRONMENTAL MORNES, PROTEINS AND METHOD FOR THE PRODUCTION THEREOF |
| EP1511769A2 (en) | 2002-05-15 | 2005-03-09 | Birgit Luber | Egf receptor antagonists in the treatment of gastric cancer |
| PL375064A1 (en) | 2002-05-20 | 2005-11-14 | Abgenix, Inc. | Treatment of renal carcinoma using antibodies against the egfr |
| EP2263691B1 (en) | 2002-07-15 | 2012-08-29 | F.Hoffmann-La Roche Ag | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| HUE025086T2 (en) | 2002-10-10 | 2016-02-29 | Merck Patent Gmbh | Pharmaceutical preparations for ERB-B1 receptor |
| CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| US20060275766A1 (en) | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
| CA2450289A1 (en) | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| AT500651B9 (de) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
| TWI333977B (en) * | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| JP4579836B2 (ja) * | 2004-01-23 | 2010-11-10 | 株式会社グリーンペプタイド | 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド |
| US20110142822A1 (en) | 2004-06-14 | 2011-06-16 | Kussie Paul H | Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| BRPI0513706A (pt) * | 2004-07-20 | 2008-05-13 | Symphogen As | anticorpo policlonal recombinante anti-rhesus d e métodos de produção |
| RU2426795C2 (ru) | 2004-07-20 | 2011-08-20 | Симфоген А/С | Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии |
| MX2007008768A (es) | 2005-01-21 | 2007-10-19 | Genentech Inc | Dosificacion fija de anticuerpos her. |
| US20070009972A1 (en) | 2005-02-16 | 2007-01-11 | Ginger Chao | Epidermal growth factor receptor polypeptides and antibodies |
| CN103251946A (zh) | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
| KR20070106029A (ko) | 2005-02-24 | 2007-10-31 | 암젠 인코포레이티드 | 상피세포 성장 인자 수용체 돌연변이 |
| US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| WO2006110478A2 (en) | 2005-04-11 | 2006-10-19 | Novartis Ag | Mutations and polymorphisms of epidermal growth factor receptor |
| CN101155932A (zh) | 2005-04-14 | 2008-04-02 | 默克专利有限公司 | 基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗 |
| WO2006116001A2 (en) | 2005-04-27 | 2006-11-02 | Welson Pharmaceuticals, Inc. | Antibodies for the treatment of cancers |
| KR101411165B1 (ko) * | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| JP2009500458A (ja) * | 2005-07-11 | 2009-01-08 | マクロジェニクス，インコーポレーテッド | ヒト化抗ｃｄ１６ａ抗体を用いる自己免疫疾患の治療方法 |
| JP2009518320A (ja) | 2005-12-05 | 2009-05-07 | シュムフォウエン アクティーゼルスカブ | 抗オルトポックスウイルス組換えポリクローナル抗体 |
| US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| KR20080113223A (ko) | 2006-03-06 | 2008-12-29 | 심포젠 에이/에스 | 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체 |
| PL2132229T3 (pl) | 2007-03-01 | 2016-12-30 | Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka | |
| MX2009008908A (es) | 2007-03-01 | 2009-08-28 | Symphogen As | Metodo para clonacion de anticuerpos analogos. |
| JP2008289483A (ja) * | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
| EP2331577B1 (en) * | 2008-08-29 | 2017-06-07 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| US9155802B2 (en) * | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
-
2008
- 2008-02-27 PL PL08706941.5T patent/PL2132229T3/pl unknown
- 2008-02-27 KR KR1020167031076A patent/KR101805140B1/ko not_active Expired - Fee Related
- 2008-02-27 MX MX2011011163A patent/MX338151B/es unknown
- 2008-02-27 CA CA2676049A patent/CA2676049C/en active Active
- 2008-02-27 JP JP2009551102A patent/JP5726417B2/ja active Active
- 2008-02-27 NZ NZ597466A patent/NZ597466A/xx not_active IP Right Cessation
- 2008-02-27 NZ NZ578943A patent/NZ578943A/xx unknown
- 2008-02-27 MX MX2009008909A patent/MX2009008909A/es active IP Right Grant
- 2008-02-27 CN CN201410211600.2A patent/CN104151430A/zh active Pending
- 2008-02-27 ES ES08706941.5T patent/ES2582386T3/es active Active
- 2008-02-27 BR BRPI0808551-0A patent/BRPI0808551B1/pt active IP Right Grant
- 2008-02-27 EP EP13187455.4A patent/EP2725036B1/en not_active Not-in-force
- 2008-02-27 KR KR1020097020519A patent/KR101676622B1/ko active Active
- 2008-02-27 EP EP08706941.5A patent/EP2132229B1/en active Active
- 2008-02-27 WO PCT/DK2008/050047 patent/WO2008104183A2/en not_active Ceased
- 2008-02-27 DK DK08706941.5T patent/DK2132229T3/en active
- 2008-02-27 AU AU2008221118A patent/AU2008221118B2/en active Active
- 2008-02-27 CN CN200880006835.0A patent/CN101675075B/zh active Active
- 2008-02-29 US US12/074,056 patent/US7887805B2/en active Active
- 2008-02-29 TW TW097107005A patent/TWI426083B/zh active
-
2009
- 2009-07-07 IL IL199725A patent/IL199725A/en active IP Right Grant
-
2010
- 2010-11-12 US US12/945,495 patent/US20110129855A1/en not_active Abandoned
- 2010-11-12 US US12/945,527 patent/US8414896B2/en active Active
-
2011
- 2011-12-08 IL IL216850A patent/IL216850A/en active IP Right Grant
-
2013
- 2013-04-26 RU RU2013119724/10A patent/RU2013119724A/ru not_active Application Discontinuation
-
2014
- 2014-10-29 HK HK14110853.9A patent/HK1197252A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535012A5 (OSRAM) | ||
| JP2022061992A5 (OSRAM) | ||
| CN114502591B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| TWI659969B (zh) | 一種抗ｐｄ－１的單株抗體及其獲得方法 | |
| JP2018502050A5 (OSRAM) | ||
| JP2020023523A5 (OSRAM) | ||
| JP2022031784A5 (OSRAM) | ||
| JP2019501883A5 (OSRAM) | ||
| JP2009535021A5 (OSRAM) | ||
| JP2019536430A5 (OSRAM) | ||
| JP2009502171A5 (OSRAM) | ||
| JP2014534242A5 (OSRAM) | ||
| JP2012530496A5 (OSRAM) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2016536322A5 (OSRAM) | ||
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| JP2012500815A5 (OSRAM) | ||
| JP2020519641A5 (OSRAM) | ||
| JP2018504105A5 (OSRAM) | ||
| JP2011514139A5 (OSRAM) | ||
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| JP2010531140A5 (OSRAM) | ||
| HRP20110187T1 (hr) | Multispecifične deimunizirane tvari koje vežu cd3 | |
| JP2012525829A5 (OSRAM) | ||
| JP2014530001A5 (OSRAM) |